Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | LOX | P28300 | 13/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715407 | 0.88 | SMN1; SMN2 (0.69) | KMT2ASMN1; SMN2HTTMEN1TSHR | |
| SCHEMBL4715831 | 0.81 | TSHR (0.60) | KMT2ASMN1; SMN2HTTMEN1TSHR | |
| SCHEMBL4715815 | 0.81 | KMT2A (0.71) | KMT2ASMN1; SMN2HTTMEN1TSHR | |
| SCHEMBL4715813 | 0.79 | KMT2A (0.69) | KMT2ASMN1; SMN2HTTMEN1TSHR | |
| SCHEMBL1856043 | 0.78 | SMN1; SMN2 (0.56) | KMT2ASMN1; SMN2HTTMEN1TSHR | |
| SCHEMBL4714622 | 0.78 | TSHR (0.56) | KMT2ASMN1; SMN2HTTMEN1TSHR | |
| SCHEMBL1854872 | 0.77 | KMT2A (0.55) | KMT2ASMN1; SMN2HTTMEN1TSHR | |
| SCHEMBL1856185 | 0.76 | SMN1; SMN2 (0.54) | KMT2ASMN1; SMN2HTTMEN1TSHR | |
| SCHEMBL1856563 | 0.76 | TSHR (0.54) | KMT2ASMN1; SMN2HTTMEN1TSHR | |
| SCHEMBL5048888 | 0.76 | SMN1; SMN2 (0.53) | KMT2ASMN1; SMN2HTTMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470102-B1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | MERCK SERONO SA (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-7592477-B2 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) | LABORATOIRES SERONO SA (CH) | 2009-09-22 | — | — | US | disclosed |
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | LABORATOIRES SERONO SA (CH) | 2009-01-15 | — | — | US | disclosed |
| EP-1986637-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | Laboratoires Serono SA (CH) | 2008-11-05 | — | — | EP | disclosed |
| CN-100410236-C | Substituted methylene amide derivatives as protein tyrosine phosphatase modulators | APPLIED RESEARCH SYSTEMS (CH) | 2008-08-13 | — | — | CN | disclosed |
| WO-2007093557-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | LABORATOIRES SERONO S.A. (CH) | 2007-08-23 | — | — | WO | disclosed |
| CN-1633410-A | Substituted methylene amide derivatives as protein tyrosine phosphatase modulators | APPLIED RESEARCH SYSTEMS (AN) | 2005-06-29 | — | — | CN | disclosed |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | APPLIED RESEARCH SYSTEMS ARS (NL) | 2005-06-09 | — | — | US | disclosed |
| EP-1470102-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | Applied Research Systems ARS Holding N.V. (AN) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003064376-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | STS, TST, SULT1A1 | KMT2A 2981/4885SMN1; SMN2 2147/4885HTT 4318/4885 |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | PTPRS, PTPA, PTPMT1 | KMT2A 740/4885SMN1; SMN2 4878/4885HTT 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.